Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report sent to investors on Friday morning. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

Shares of Oragenics stock opened at $1.27 on Friday. The stock has a market capitalization of $7.09 million, a PE ratio of -0.15 and a beta of 0.50. Oragenics has a 52-week low of $0.86 and a 52-week high of $7.74. The business has a 50-day moving average price of $1.13.

Oragenics (NYSE:OGEN) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC purchased a new position in Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent reporting period. Institutional investors and hedge funds own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.